Press Releases Archive
2017-2023
- Taiho Oncology and Astex Pharmaceuticals Announce Data Presentations at the 65th ASH Annual Meeting 17 November 2023
- Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia 19 September 2023
- Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting 12 December 2022
- European Medicines Agency commences review of oral fixed-dose combination of decitabine and cedazuridine for the treatment of adults with acute myeloid leukemia 22 August 2022
- Astex announces that the phase 3 ASCERTAIN – acute myeloid leukemia (AML) clinical study of oral hypomethylating agent decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) met the trial’s primary endpoint 12 May 2022
- Oral decitabine and cedazuridine (ASTX727) granted Orphan Drug Designation (ODD) by the European Commission for the treatment of Acute Myeloid Leukemia (AML) 6 January 2022
- Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes 23 September 2021
- NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology 14 April 2021
- Astex Pharmaceuticals expands clinical evaluation of oral decitabine and cedazuridine tablets through new Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) 28 October 2020
- Astex and Otsuka announce results of phase 3 ASTRAL-2 and ASTRAL-3 studies of guadecitabine (SGI-110) in patients with previously treated acute myeloid leukemia (AML) and myelodysplastic syndromes or chronic myelomonocytic leukemia (MDS/CMML) 14 October 2020
- Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia 8 September 2020
- Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA 31 August 2020
- Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets. 7 July 2020
- Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML 11 February 2020
- Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL. 9 December 2019
- Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates 7 June 2019
- Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy 30 July 2018
2016
- Astex to Showcase Its Next-Generation Hypomethylating Agents Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology 29 November 2016
- Astex Joins the Dementia Discovery Fund as a Strategic Investor 21 November 2016
- Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (ribociclib) plus letrozole as a first-line treatment for HR+/HER2- Advanced Breast Cancer 1 November 2016
- Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka’s Subsidiary Astex Pharmaceuticals 20 October 2016
- Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia 19 April 2016
2013
- Astex Pharmaceuticals to Present at AACR-NCI-EORTC 14 October 2013
- Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals 11 October 2013
- Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress 30 September 2013
- Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash 5 September 2013
- Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study 28 August 2013
- Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results 1 August 2013
- Astex Pharmaceuticals to Announce 2013 Second Quarter Financial Results on August 1st 29 July 2013
- Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of Resistance in Preclinical Models 22 July 2013
- Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator 8 July 2013
- Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO) 20 June 2013
- Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study inPatients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association 14 June 2013
- Astex Pharmaceuticals Reports 2013 First Quarter Financial Results 29 April 2013
- Astex Pharmaceuticals to Announce 2013 First Quarter Financial Results on April 29th 22 April 2013
- Astex Pharmaceuticals Provides SGI-110 Update 10 April 2013
- Astex Pharmaceuticals Pipeline Data Presentations at AACR 3 April 2013
- Astex Pharmaceuticals Reports 2012 Fourth Quarter and Year-End Financial Results 25 February 2013
- Astex Pharmaceuticals to Announce 2012 Fourth Quarter and Year-End Financial Results on February 25th 19 February 2013
- Cancer Research UK and Cancer Research Technology Initiate AT13148 Clinical Trial to Treat Several Cancer Types 16 January 2013
- Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients 2 January 2013
2012
- Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH 10 December 2012
- Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda 4 December 2012
- Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH 20 November 2012
- Astex Pharmaceuticals to Present at EORTC-NCI-AACR 31 October 2012
- Astex Pharmaceuticals Reports 2012 Third Quarter Financial Results 30 October 2012
- Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance 29 October 2012
- Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer 24 October 2012
- Astex Pharmaceuticals to Announce 2012 Third Quarter Financial Results on October 30, 23 October 2012
- Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals 15 October 2012
- Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors 10 October 2012
- Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union 9 October 2012
- Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients 2 October 2012
- DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia 28 September 2012
- Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program 21 September 2012
- Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients 10 September 2012
- Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration 6 September 2012
- Astex Pharmaceuticals to Participate on Epigenetics Panel at Rodman & Renshaw Conference 4 September 2012
- Astex President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery 20 August 2012
- Astex Pharmaceuticals Reports 2012 Second Quarter Financial Results 30 July 2012
- Astex Pharmaceuticals to Announce 2012 Second Quarter Financial Results on July 30, 24 July 2012
- DACOGEN(R) Receives a Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia 20 July 2012
- Astex Board Member Wins 2012 European Mediscience Award 10 July 2012
- Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 22 June 2012
- Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor 13 June 2012
- Astex Pharmaceuticals to Present at ASCO Annual Meeting 16 May 2012
- Astex Pharmaceuticals Reports 2012 First Quarter Financial Results 30 April 2012
- Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results on April 30, 2012 24 April 2012
- Astex Pharmaceuticals to Present AT26893, a Novel Targeted Approach to the Treatment of HCV at EASL 13 April 2012
- Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 MDS and AML Data Presentation at AACR 3 April 2012
- Astex Pharmaceuticals to Present at AACR Annual Meeting 29 March 2012
- Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda 21 March 2012
- Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia 6 March 2012
- Astex Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial Results 5 March 2012
- Astex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012 28 February 2012
- Astex Pharmaceuticals to Host Annual Analyst and Investor Day on March 27, 2012 16 February 2012
- FDA’s Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid Leukemia 9 February 2012
- Astex Announces Early Transfer of Epigenetics Project to GSK 16 January 2012
2011
- Astex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML 29 December 2011
- Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results 31 October 2011
- Astex Pharmaceuticals to Present a Novel Targeted Approach to the Treatment of HCV at the AASLD Meeting 31 October 2011
- Evidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCO 27 September 2011
- SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website 12 September 2011
- SuperGen Reports 2011 Second Quarter Financial Results 3 August 2011
- FDA Accepts DACOGEN® (Decitabine) sNDA Submission in Acute Myeloid Leukemia 13 July 2011
- SuperGen President & CEO Elected to BIO Board of Directors 28 June 2011
- SuperGen Stockholders Approve Stock Issuance In Connection with the Proposed Acquisition of Astex Therapeutics Limited 16 June 2011
- Eisai and Janssen Announce the Presentation of DACOGEN® (decitabine) Data at ASCO from a Phase III Study in Patients with Acute Myeloid Leukemia 6 June 2011
- Astex Therapeutics and Cambridge Crystallographic Data Centre Extend 10-Year Research Collaboration 12 May 2011
- Astex Achieves Milestones in GSK Collaboration 3 May 2011
- SuperGen Reports 2011 First Quarter Financial Results 27 April 2011
- Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca 12 April 2011
- SuperGen and Astex Therapeutics Enter Definitive Merger Agreement 6 April 2011
- SuperGen to Webcast 5th Annual Investor & Analyst Day on April 12, 2011 31 March 2011
- SuperGen PIM Kinase Presentations at AACR 31 March 2011
- Astex To Present Data From Its FGFR Inhibitor Programme at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 29 March 2011
- SuperGen Reports 2010 Fourth Quarter and Year-End Financial Results 28 February 2011
- Astex Receives Milestone from Wellcome Trust for Pioneering HCV Research 1 February 2011
- Astex Announces Milestone in Oncology Collaboration 11 January 2011
- SuperGen Announces Enrollment of First Patient in First in Human Trial of SGI-110 in MDS and AML Patients 5 January 2011
2010
- SuperGen Announces Presentation of SGI-110 Preclinical Data at American Society of Hematology 3 December 2010
- Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH 1 December 2010
- SuperGen Pipeline Presentations at EORTC-NCI-AACR 15 November 2010
- Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting 11 November 2010
- SuperGen Discontinues Clinical Development of SGI-1776 10 November 2010
- Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma 4 November 2010
- SuperGen Reports 2010 Third Quarter Financial Results 25 October 2010
- Milestone transition in Astex Alzheimer’s Disease collaboration with AstraZeneca 25 October 2010
- Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma 12 October 2010
- Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma 12 August 2010
- SuperGen Reports 2010 Second Quarter Financial Results 2 August 2010
- Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry 29 July 2010
- Dacogen® (Decitabine) for Injection Phase III AML Results Announced 30 June 2010
- Encouraging Interim Data From A Phase I Study Of Astex’s HSP90 Inhibitor AT13387 To Be Presented At ASCO 2 June 2010
- SuperGen Reports 2010 First Quarter Financial Results 26 April 2010
- Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010 13 April 2010
- SuperGen Reports 2009 Fourth Quarter and Year-End Financial Results 1 March 2010
- Astex Executive Receives the AstraZeneca Business Development Professional of the Year 2009 Award 9 February 2010
- Clinical Candidate From PKB/AKT Collaboration With Astex Selected by AstraZeneca 7 January 2010
2009
- Astex Wins Company Newsflow of the Year Award 11 December 2009
- SuperGen Data Presentations at American Society of Hematology (ASH) Annual Meeting 1 December 2009
- Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe 23 November 2009
- Astex Announces Strategic Drug Discovery Alliance with GlaxoSmithKline 12 November 2009
- SuperGen Presentations at AACR-NCI-EORTC 9 November 2009
- Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC Annual Meeting 2009 9 November 2009
- Astex Announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387 3 November 2009
- SuperGen Reports 2009 Third Quarter Financial Results 26 October 2009
- SuperGen and GSK to Collaborate on the Discovery and Development of Novel Epigenetic Therapeutics 26 October 2009
- David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics 21 September 2009
- SuperGen’s MP-470 Demonstrates Clinical Benefit in Small Cell Lung Cancer and Neuroendocrine Tumor Patients 3 August 2009
- SuperGen Reports 2009 Second Quarter Financial Results 27 July 2009
- SuperGen Names Mohammad Azab, M.D., Chief Medical Officer 21 July 2009
- Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009 16 May 2009
- SuperGen’s MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients 4 May 2009
- SuperGen Announces Departure of Chief Medical Officer 1 May 2009
- SuperGen Reports 2009 First Quarter Financial Results 27 April 2009
- SuperGen Identifies New Class of Etk/Bmx Kinase Inhibitors 21 April 2009
- SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting 21 April 2009
- Astex Reports Positive Clinical Biomarker Data from its Phase I study on CDK Inhibitor AT7519 at the AACR Annual Meeting 2009 14 April 2009
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 13 April 2009
- SuperGen to Webcast 4th Annual Analyst Day on April 14, 2009 7 April 2009
- Astex Achieves Milestones in Drug Discovery Collaboration 31 March 2009
- Astex Awarded £2 Million from Wellcome Trust for Pioneering HCV Research 24 March 2009
- SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results 2 March 2009
- Astex Receives Award from the Multiple Myeloma Research Foundation to Support Clinical Development of AT7519 2 March 2009
- Astex Scientists Solve Structure of Cyclin Dependent Kinase 4 24 February 2009
- Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers 11 February 2009
2008
- SuperGen Appoints David Bearss, Ph.D., Chief Scientific Officer 17 November 2009
- SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia 8 December 2008
- SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition 2 December 2008
- Astex presents updates on AT7519 and AT9283 at the American Society of Hematology (ASH) Conference 1 December 2008
- SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor 20 November 2008
- SuperGen Reports 2008 Third Quarter Financial Results 4 November 2008
- SuperGen’s MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 23 October 2008
- SuperGen to Present Data at EORTC-NCI-AACR 15 October 2008
- Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment 29 September 2008
- SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme 7 August 2008
- SuperGen Reports 2008 Second Quarter Financial Results 4 August 2008
- SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen® Versus Supportive Care in Patients With Myelodysplastic Syndromes 1 July 2008
- SuperGen’s JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation 16 June 2008
- SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models 13 June 2008
- Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. 9 June 2008
- Astex Drug Candidates to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting 28 May 2008
- SuperGen Reports 2008 First Quarter Financial Results 28 April 2008
- SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008 22 April 2008
- Royal Society of Chemistry recognises Astex Scientists 22 April 2008
- SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models 16 April 2008
- Data Show SuperGen’s MP-470 is Safe in Humans 15 April 2008
- SuperGen’s MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib 14 April 2008
- Astex Drug Candidates to be Presented at the 2008 AACR Annual Meeting 8 April 2008
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 7 April 2008
- SuperGen’s DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 14 March 2008
- SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 3 March 2008
- Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance 6 February 2008
2007
- SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor 17 December 2007
- SuperGen’s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting 10 December 2007
- SuperGen’s CLIMB™ Technology Identifies Lead Pim Kinase Inhibitors 10 December 2007
- Data Indicate That SuperGen’s Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models 10 December 2007
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology’s 49th Annual Meeting 3 December 2007
- Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 29 November 2007
- Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme 31 October 2007
- SuperGen Reports 2007 Third Quarter Financial Results 29 October 2007
- Data Support use of SuperGen’s CLIMB Technology in Lead Development and Optimization 25 October 2007
- Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents 25 October 2007
- SuperGen’s Novel Hypomethylating Agent Highlighted at AACR Plenary Session 25 October 2007
- SuperGen to Webcast Investigator/Analyst Pipeline Update Presentation October 24 18 October 2007
- Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 18 October 2007
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 17 October 2007
- Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer 17 August 2007
- SuperGen Reports 2007 Second Quarter Financial Results 2 August 2007
- SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor 5 July 2007
- SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board 30 May 2007
- SuperGen Names Gregory Berk, M.D., Chief Medical Officer 29 May 2007
- SuperGen to Participate in Brean Murray Carret & Co. Healthcare & Biotechnology Small Cap One-on-One Conference 11 May 2007
- SuperGen Reports 2007 First Quarter Financial Results 2 May 2007
- SuperGen to Release 2007 First Quarter Financial Results May 2 27 April 2007
- SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470 27 April 2007
- Supergen Sells Select Non-Core Assets to Intas 20 April 2007
- Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 19 April 2007
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR 4 April 2007
- Nipent® Acquisition by Hospira is Complete 3 April 2007
- SuperGen Reports 2006 Fourth Quarter and Year-End Financial Results 14 March 2007
- SuperGen to Present Discovery Platform and Pipeline Update at Analyst and Investor Day 2 March 2007
- SuperGen to Release 2006 Fourth Quarter and Year-End Financial Results March 14 1 March 2007
- SuperGen to Webcast March 2 Analysts and Investor Day 1 March 2007
2006
- Astex Therapeutics Appoints John Aston Chief Financial Officer 4 December 2006
- Mayne Pharma Acquires Remaining Nipent® Rights 27 November 2006
- SuperGen Presents Preclinical Data on Selected Lead Kinase Compounds and DNA Methylation Inhibitor at EORTC 10 November 2006
- SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design 9 November 2006
- SuperGen Reports 2006 Third Quarter Financial Results 9 November 2006
- SuperGen COO to Leave Company at Year-End 4 October 2006
- Astex Therapeutics initiates clinical trial with investigational anti-cancer drug AT9283 26 September 2006
- Mayne Pharma’s Purchase of SuperGen’s North American Oncology Products Completes 23 August 2006
- New anti-cancer drug discovery alliance between GlaxoSmithKline, the Wellcome Trust and The Institute of Cancer Research, focused on B-RAF inhibitors, builds on partnership between Astex, the Wellcome Trust, the Institute of Cancer Research and Cancer Res 27 July 2006
- SuperGen Reports 2006 Second Quarter Financial Results 27 July 2006
- SuperGen Announces Attainment of Milestone from the MGI PHARMA / Cilag GmbH, a Johnson & Johnson Company, Licensing for Dacogen(TM) (Decitabine) for Injection 6 July 2006
- Mayne Acquires SuperGen’s North American Oncology Products 21 June 2006
- SuperGen Completes Contract to Transition Wyeth Distribution of Nipent® Outside of the U.S. 6 June 2006
- SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection) 2 June 2006
- SuperGen Announces Achievement of $20 Million Dacogen™ (decitabine) Injection Milestone 26 May 2006
- SuperGen to Webcast Analyst & Investor Day 19 May 2006
- U.S. FDA Approves Dacogen™ (Decitabine) For Injection 3 May 2006
- SuperGen Announces Interim Results of Orathecin™ Combination Trial in Pancreatic Cancer 26 April 2006
- Astex Therapeutics announces IND approval for novel cancer drug AT9283 25 April 2006
- SuperGen Reports 2006 First Quarter Financial Results 20 April 2006
- SuperGen Completes Acquisition of Montigen Pharmaceuticals 5 April 2006
- SuperGen Announces Results From Combination Study in CLL Published in the Journal of Clinical Oncology 14 March 2006
- Astex announces new drug discovery collaboration with University of Newcastle upon Tyne and Cancer Research Technology Limited 13 March 2006
- SuperGen Reports 2005 Fourth Quarter and Year-End Financial Results 23 February 2006
- SuperGen Announces Signing of Definitive Agreement to Acquire Montigen Pharmaceuticals 27 January 2006
- SuperGen Announces Withdrawal of Orathecin™ Marketing Authorization Application 20 January 2006
- Studies of Nipent® in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting 9 December 2005
2005
- Dacogen™ (Decitabine) Injection Complete Response Accepted for Review by U.S. FDA 15 December 2005
- Dacogen™ (Decitabine) Injection Data Presented at American Society of Hematology (ASH) Annual Meeting 12 December 2005
- Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs 6 December 2005
- MGI PHARMA and SuperGen Provide Regulatory Status Updates for Dacogen™ (decitabine) Injection for MDS 15 November 2005
- SuperGen Reports 2005 Third Quarter Financial Results 20 October 2005
- Approvable Letter Received from the FDA for Dacogen™ (Decitabine) Injection for the Treatment of MDS 1 September 2005
- AstraZeneca and Astex announce new anti-cancer drug discovery alliance 27 July 2005
- SuperGen Reports 2005 Second Quarter Financial Results 21 July 2005
- Astex announces IND approval for novel cancer drug AT7519 27 June 2005
- Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months 23 May 2005
- SuperGen Reports Results of Phase III Rescue Study With Orathecin™ (Rubitecan Capsules) Versus 5-FU in Pancreatic Cancer Patients 16 May 2005
- SuperGen Reports 2005 First Quarter Financial Results 21 April 2005
- SuperGen Appoints Allan R. Goldberg, Ph.D. to Board of Directors 8 March 2005
- SuperGen Initiates Phase II Combination Trial of Orathecin™ and Gemcitabine in Chemotherapy Naive Pancreatic Cancer Patients 3 March 2005
- SuperGen Reports 2004 Fourth Quarter and Year-End Financial Results 24 February 2005
- Dr. Joseph Rubinfeld Resigns From Supergen’s Board Of Directors 9 February 2005
- Dacogen™ NDA Accepted for Filing by FDA 3 January 2005
- SuperGen Announces Withdrawal of Orathecin™ NDA 3 January 2005
2004
- Studies Exploring Nipent® in Combination Cancer Therapies in the Treatment of Graft-Versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting 6 December 2004
- Astex chosen by the World Economic Forum as a Technology Pioneer for 2005 6 December 2004
- SuperGen Announces 90 Day Extension of FDA Review Date for Orathecin™ New Drug Application 29 November 2004
- SuperGen Granted FDA Approval of Paclitaxel ANDA 15 November 2004
- SuperGen and MGI PHARMA Announce Submission of Dacogen™ NDA to U.S. FDA 1 November 2004
- SuperGen and MGI PHARMA Announce Acceptance of Dacogen™ MAA for Review by EMEA 25 October 2004
- SuperGen Reports Third Quarter Financial Results 21 October 2004
- SuperGen and MGI PHARMA Announce Submission of MAA for Approval of Dacogen™ in Europe 1 October 2004
- MGI PHARMA and SuperGen Announce Closing of Stock Purchase Agreement and Effectiveness of License Agreement 22 September 2004
- MGI PHARMA and SuperGen Announce Signing of a Worldwide License Agreement for Dacogen™ 1 September 2004
- SuperGen Reports Second Quarter Financial Results 22 July 2004
- SuperGen Announces Publication of Phase II Studies of Dacogen™ in Advanced MDS Patients 9 July 2004
- SuperGen Submits Application for EMEA Approval of Orathecin™ 2 July 2004
- SuperGen Reports Results of Ongoing Studies of Nipent® in Combination Therapies for Chronic Lymphocytic Leukemia and Low Grade B-cell Lymphomas 10 June 2004
- SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin for Treatment of Advanced Solid Tumors 9 June 2004
- SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™ 1 June 2004
- SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS 24 May 2004
- SuperGen Announces Study of Novel Regimen Using Nipent® for Hematopoietic Stem Cell Transplantation Published in Journal of Bone Marrow Transplantation 21 May 2004
- SuperGen Reports 2004 First Quarter Financial Results 23 April 2004
- SuperGen Announces FDA Acceptance of Rolling NDA Request for Dacogen™ 22 April 2004
- SuperGen (Nasdaq: SUPG) Will Webcast Its Scientific Review and Corporate Update for Investors 20 April 2004
- Astex achieves second milestone in Alzheimer’s drug discovery collaboration with AstraZeneca 19 April 2004
- SuperGen Reports Results from Dacogen™ Phase III Study in Myelodysplastic Syndromes (MDS) 31 March 2004
- SuperGen’s New Drug Application for Orathecin™ (rubitecan) Capsules Accepted by FDA for Filing 26 March 2004
- Astex, The Wellcome Trust, The Institute of Cancer Research and Cancer Research Technology announce major cancer drug discovery collaboration 22 March 2004
- SuperGen Note Holders Release $10.6 Million in Escrowed Funds 10 March 2004
- SuperGen Releases Interim Data Clarification From Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome Following Analyst/Investigator Conference Call 10 March 2004
- SuperGen Announces Private Placement of $34 Million of Stock and Warrants 5 March 2004
- Published Study Results Show Low-Dose Outpatient Dosing Schedule of Dacogen™ Useful in Patients With Hematological Malignancies 2 March 2004
- SuperGen Reports 2003 Fourth Quarter and Year-End Financial Results 26 February 2004
- Webcast Alert: SuperGen Presentation at Informed Investors Biotech/Healthcare Virtual Forum to be Webcast On Thursday, February 26, 2004, 10:30 am ET 25 February 2004
- SuperGen Acquires European Marketing Authorizations for Nipent® from Pfizer 24 February 2004
- SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock 23 February 2004
- SuperGen Announces Interim Data from Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome 13 February 2004
- SuperGen, Inc. Announces Filing of Registration Statement for Public Offering of Shares of Common Stock 4 February 2004
- SuperGen Announces Resignation of Dr. Craig Rosenfeld To Pursue Start-Up Opportunity 30 January 2004
- SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer 27 January 2004
- Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome 23 January 2004
© Astex Pharmaceuticals
All rights reserved
